NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Functional Role of Hepatitis C Virus NS5A in the Regulation of Autophagy.Pathogens (Basel, Switzerland) · 2024
   Review
2. Androgen Receptor Is Inactivated and Degraded in Bladder Cancer Cells by Phenyl Glucosamine via miR-449a Restoration.Medical science monitor : international medical journal of experimental and clinical research · 2018
   Article
3. Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis.Hepatitis monthly · 2016
   Review
4. The role of HCV proteins on treatment outcomes.Virology journal · 2015
   Review
5. Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy.World journal of gastroenterology · 2014
   Review
6. Potent Hepatitis C Virus NS5A Inhibitors Containing a Benzidine Core.ACS medicinal chemistry letters · 2014
   Article
7. HCV direct-acting antiviral agents: the best interferon-free combinations.Liver international : official journal of the International Association for the Study of the Liver · 2014
   Review
8. Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.Bioorganic & medicinal chemistry letters · 2013
   Article
9. Intrinsically unstructured domain 3 of hepatitis C Virus NS5A forms a "fuzzy complex" with VAPB-MSP domain which carries ALS-causing mutations.PloS one · 2012
   Article

Corrections and comments

• Comment on
  Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.2010

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.